中国香港、上海和美国新泽西州：2024年4月5日，星期五：和黄医药(中国)有限公司 (简称 "和黄医药" 或 "HUTCHMED") (纳斯达克/伦敦证交所: HCM; 香港交易所: 13) 今日宣布将于2024年4月5日至10日在美国加利福尼亚州圣地亚哥召开的美国癌症研究协会 (AACR) 2024年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。
标题：HMPL-506 (一种新型、强效、差异化的 menin-MLL 抑制剂) 治疗临床前MLL 重排和 NPM1 突变的急性白血病
HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearranged and NPM1mutant acute leukemia in preclinical models
标题：新型 CD38 靶向抗体偶联药物 (ADC) HMA800067在临床前 B 细胞恶性肿瘤模型中表现出优于达雷妥尤单抗的抗肿瘤活性
HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
标题：HMPL-295 (一种强效、选择性的 ERK1/2 抑制剂) 的临床前特征
Preclinical characterization of HMPL-295, a potent and selective ERK1/2 inhibitor
标题：靶向 YAP1/TEAD信号通路使 KRAS 驱动的肿瘤细胞对 MAPK/ERK 通路抑制剂重新敏感
Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS-driven cancer cells
标题：Syk 抑制剂索乐匹尼布 (HMPL-523) 在复发或难治性淋巴瘤患者中的安全性和有效性
Safety and Efficacy of Sovleplenib (HMPL-523), a Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma
标题：早期癌胚抗原 (CEA) 动态预测呋喹替尼 + 最佳支持治疗在FRESCO-2研究中入组的转移性结直肠癌患者的疗效
Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
标题：赛沃替尼+奥希替尼对比赛沃替尼+ 安慰剂，用于治疗奥希替尼治疗后进展的 EGFR 突变 、MET 扩增的晚期非小细胞肺癌患者
Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
标题：通过ROS依赖性铁死亡增强抗癌疗效: 索凡替尼和顺铂在小细胞肺癌中的协同作用
Enhanced anticancer efficacy via ROS-dependent ferroptosis: synergy between surufatinib and cisplatin in small cell lung cancer
标题：索凡替尼治疗非小细胞肺癌的疗效及作用机制
Efficacy and underlying mechanisms of surufatinib in non-small cell lung cancer treatment
标题：增强胆管癌的放射敏感性: 索凡替尼在肿瘤抑制和巨噬细胞重新编程中的双重作用
Enhancing Radiosensitivity in Biliary Tract Cancer: The Dual Role of Surufatinib in Tumor Suppression and Macrophage Reprogramming
标题：索凡替尼治疗胰腺癌: 揭示GPR34在肿瘤相关巨噬细胞及增强免疫疗法疗效中的作用
Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in TAMs and enhancing immunotherapy efficacy
标题：索凡替尼联合PD-1单抗和化疗治疗胰腺癌的疗效及作用机制
Efficacy and Underlying Mechanisms of Surufatinib Combined with PD-1 Monoclonal Antibody and Chemotherapy in Pancreatic Cancer
标题：优化放射疗法联合VEGFR-TKI和PD-(L)1抑制剂治疗转移性结直肠癌的治疗方案
Optimizing the treatment schedule of radiotherapy combined with VEGFR-TKIs and PD-(L) 1 inhibitors in metastatic colorectal cancer
标题：神经内分泌分化的临床和流行病学概况 — 一项基于医院的回顾性研究
Clinical and epidemiological profile of neuroendocrine differentiation- A hospital-based retrospective study
标题：神经内分泌分化型胃癌的流行病学特征及治疗策略
Epidemiological characteristics and treatment strategies of gastric cancer with neuroendocrine differentiation (NED)
标题：索凡替尼联合信迪利单抗和 IBI310 治疗高级别晚期神经内分泌肿瘤患者的初步疗效: 一项多中心、单臂II 期研究
Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study
